Welcome to our dedicated page for Sensus Healthcare news (Ticker: SRTS), a resource for investors and traders seeking the latest updates and insights on Sensus Healthcare stock.
Overview of Sensus Healthcare Inc.
Sensus Healthcare Inc. (Nasdaq: SRTS) is a specialized medical device company dedicated to advancing the field of non-invasive treatments for both oncological and non-oncological skin conditions. Headquartered in Boca Raton, Florida, the company has carved a niche in the healthcare industry through its proprietary superficial radiation therapy (SRT) technology. This innovative, low-energy X-ray radiation technology is the result of over a decade of rigorous research and development, enabling safe, effective, and cost-efficient treatment of conditions such as non-melanoma skin cancers (including basal and squamous cell carcinomas) and keloids.
Core Technology and Product Portfolio
At the heart of Sensus Healthcare's offerings is its proprietary SRT technology, which has been seamlessly integrated into its flagship devices, the SRT-100™ and SRT-100 Vision™. These devices are engineered to deliver precise, localized radiation therapy, making them ideal for outpatient settings. The company's products are designed to provide an alternative to surgical interventions, offering patients a painless, non-invasive treatment option with minimal downtime. Additionally, Sensus supports its customers through a comprehensive Sentinel Service Program, ensuring optimal device performance and customer satisfaction.
Market Applications and Value Proposition
Sensus Healthcare's devices address critical needs in dermatology and oncology, particularly in the treatment of non-melanoma skin cancers, which are among the most common forms of cancer globally. The company's technology also provides a unique solution for treating keloids, a condition often resistant to traditional therapies. By focusing on non-invasive, cost-effective, and patient-friendly treatment options, Sensus Healthcare appeals to a broad spectrum of healthcare providers, including dermatologists, oncologists, and hospital outpatient departments.
Industry Context and Competitive Landscape
The medical device industry is characterized by rapid technological advancements and a growing emphasis on non-invasive treatment modalities. Sensus Healthcare operates within this dynamic environment, competing with companies offering surgical, laser-based, or alternative radiotherapy solutions. Its differentiation lies in the proprietary nature of its SRT technology, which combines clinical efficacy with patient comfort. The company's commitment to research and development further strengthens its position, enabling it to address evolving market demands and maintain a competitive edge.
Revenue Model and Geographic Focus
Sensus Healthcare primarily generates revenue through the direct sale of its devices, complemented by service programs and potential licensing opportunities. The company's customer base is predominantly located in the United States, though its technology has global applicability, given the universal prevalence of the conditions it addresses.
Conclusion
Sensus Healthcare Inc. exemplifies innovation in the medical device industry, leveraging its proprietary SRT technology to offer non-invasive, effective, and patient-centric solutions for skin conditions. With a strong focus on R&D and a well-defined market niche, the company is well-positioned to meet the growing demand for advanced treatment options in dermatology and oncology. Its commitment to improving patient outcomes underscores its significance in the healthcare sector.
Sensus Healthcare (SRTS) reported a strong third quarter for 2021, achieving revenues of $5.5 million, a 244% increase from $1.6 million in Q3 2020. This marks the company’s first profitable quarter, with a net income of $0.2 million or $0.01 per diluted share, improving from a net loss of $(1.7) million a year prior. The company shipped 14 systems during the quarter and reaffirmed expectations for continued growth and profitability into Q4 and 2021. Cash reserves stood at $16.4 million with no long-term debt.
Sensus Healthcare, Inc. (Nasdaq: SRTS) will hold a conference call on November 4, 2021, at 4:30 p.m. Eastern time to discuss its third quarter 2021 financial results. Management will provide a business update and discuss recent and upcoming milestones. Investors can access the call by dialing 800-285-6670 (U.S.) or 832-553-9961 (International), and the call will also be available via live webcast. Following the call, a replay will be accessible via telephone and online. Sensus Healthcare specializes in non-invasive treatments for oncological and non-oncological conditions.
Sensus Healthcare, Inc. (Nasdaq: SRTS) will host a virtual fireside chat with CEO Joseph Sardano and CFO Javier Rampolla on October 19, 2021, at 11:00 a.m. ET. This session, organized by Maxim Group LLC and M-Vest, invites professional investors to register in advance. A 48-hour replay will be available post-event on the company’s investor website. Sensus Healthcare specializes in innovative, non-invasive treatments for oncological and non-oncological conditions, including its Sculptura™ system and SRT-100™ technology.
Sensus Healthcare (Nasdaq: SRTS) has received a five-year license renewal from the Chinese Health Authority to market its SRT-100™ system for treating non-melanoma skin cancer and keloids in Greater China. The new license, effective until December 2026, reflects the company's successful presence with 46 units installed in various medical facilities across China. The CEO expressed optimism about post-pandemic sales recovery and remarked on a new distribution agreement with Ekpac Healthcare. Sensus also anticipates marketing authorization for its Sculptura™ system by late 2022.
Sensus Healthcare (Nasdaq: SRTS) announces participation in the upcoming Fall Clinical Dermatology Conference from October 21-24, 2021, in Las Vegas. Over 1,200 physicians are registered to attend this first major in-person dermatology event in 18 months. Key opinion leaders will present on superficial radiation therapy (SRT) for non-melanoma skin cancer. CEO Joe Sardano emphasizes strong sales momentum for the second half of 2021, driven by favorable reimbursement changes and a backlog of orders. Sensus anticipates achieving profitability this year.
Sensus Healthcare (Nasdaq: SRTS), based in Boca Raton, Fla., will be presenting at the H.C. Wainwright 23rd Annual Global Investment Conference, held virtually from September 13 to 15, 2021. CEO Joe Sardano's presentation will be accessible via a webcast starting at 7:00 am (EST) on September 13. Sensus Healthcare specializes in non-invasive treatments for both oncological and non-oncological conditions, featuring technologies like the Sculptura™ and SRT-100™ systems, aimed at enhancing patient quality of life.
Sensus Healthcare (SRTS) reported Q2 2021 revenues of $5.4 million, a 358% increase year-over-year and 77% sequentially. The net loss narrowed to $(0.3) million or $(0.02) per share, improving from $(2.6) million or $(0.16) per share in Q2 2020. The company shipped 17 systems, enhancing its installed base to 515 systems. Cash stood at $15.2 million with no long-term debt. Management expressed optimism for continued growth, aided by new reimbursement schedules and an expanded international strategy, particularly in China and India.
Sensus Healthcare, Inc. (Nasdaq: SRTS) will hold a conference call on August 5, 2021, at 4:30 p.m. Eastern to discuss its Q2 2021 financial results and provide business updates. The call will be accessible via dial-in numbers and a live webcast. Sensus is focused on non-invasive medical treatments for various conditions, including its Sculptura™ and SRT systems for cancer treatment and skin conditions. This call aims to communicate recent achievements and future milestones.
Sensus Healthcare (Nasdaq: SRTS), a leader in non-invasive medical devices, announced management's participation in A.G.P.’s Virtual MedTech Summer Conference on July 29, 2021. The conference will facilitate one-on-one virtual meetings with investors. Sensus specializes in innovative treatments for oncological and non-oncological conditions, including the Sculptura™ system for radiation therapy and SRT-100™ for treating skin cancers. The company's focus is on enhancing patient quality of life through advanced technologies.
Sensus Healthcare reported an 83% revenue increase year-over-year, achieving $3.1 million in the first quarter of 2021 compared to $1.7 million in 2020. The company installed its 500th unit and narrowed its net loss to $1.1 million or $0.07 per share, down from $3.6 million or $0.22 per share last year. Gross profit rose to $1.6 million, with a gross margin of 51.6%. Cash and equivalents totaled $13.7 million as of March 31, 2021. Management anticipates continued revenue growth driven by higher reimbursement rates and expanding market acceptance.
FAQ
What is the current stock price of Sensus Healthcare (SRTS)?
What is the market cap of Sensus Healthcare (SRTS)?
What does Sensus Healthcare Inc. do?
What conditions does Sensus Healthcare's technology treat?
How does Sensus Healthcare generate revenue?
What makes Sensus Healthcare's technology unique?
Who are the primary customers of Sensus Healthcare?
What is the SRT-100 Vision™ device?
What challenges does Sensus Healthcare face in its market?
Where is Sensus Healthcare based?
What is the Sentinel Service Program by Sensus Healthcare?
What is superficial radiation therapy (SRT)?
